Prolonged sulforaphane treatment does not enhance tumorigenesis in oncogenic K-ras and xenograft mouse models of lung cancer
Background: Sulforaphane (SFN), an activator of nuclear factor erythroid-2 related factor 2 (Nrf2), is a promising chemopreventive agent which is undergoing clinical trial for several diseases. Studies have indicated that there is gain of Nrf2 function in lung cancer and other solid tumors because o...
Main Authors: | Ponvijay Kombairaju, Jinfang Ma, Rajesh K Thimmulappa, G Shengbin Yan, Edward Gabrielson, Anju Singh, Shyam Biswal |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2012-01-01
|
Series: | Journal of Carcinogenesis |
Subjects: | |
Online Access: | http://www.carcinogenesis.com/article.asp?issn=1477-3163;year=2012;volume=11;issue=1;spage=8;epage=8;aulast=Kombairaju |
Similar Items
-
Sulforaphane Impact on Reactive Oxygen Species (ROS) in Bladder Carcinoma
by: Hui Xie, et al.
Published: (2021-05-01) -
Role of Keap1-Nrf2 Signaling in Anhedonia Symptoms in a Rat Model of Chronic Neuropathic Pain: Improvement With Sulforaphane
by: Shan Li, et al.
Published: (2018-08-01) -
Chemopreventive Activities of Sulforaphane and Its Metabolites in Human Hepatoma HepG2 Cells
by: Peng Liu, et al.
Published: (2018-05-01) -
A Bibliometric Review of the Keap1/Nrf2 Pathway and its Related Antioxidant Compounds
by: Ana Paunkov, et al.
Published: (2019-09-01) -
Nrf2 and Keap1 Abnormalities in 104 Lung Adenocarcinoma Cases and Association with Clinicopathologic Features
by: Yu XIAO, et al.
Published: (2018-03-01)